Longitudinal CSF isoprostane and MRI atrophy in the progression to AD

Journal of Neurology

Volumn 254, Issue 12, 2007, Pages 1666-1675

  De Leon, M J ^a,c   Mosconi, L ^a   Li, J ^a   De Santi, S ^a   Yao, Y ^d   Tsui, W H ^a,c   Pirraglia, E ^a   Rich, K ^a   Javier, E ^a   Brys, M ^a   Glodzik, L ^a   Switalski, R ^a   Saint Louis, L A ^a,e   Pratico, D ^b,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Department of Obstetrics Gynecology   (United States)

Author keywords

Alzheimer's disease; CSF biomarkers; Isoprostane; Longitudinal

Indexed keywords

BIOLOGICAL MARKER; ISOPROSTANE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MEMORY DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TEMPORAL LOBE; VOLUNTEER;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ATROPHY; BRAIN MAPPING; COGNITION DISORDERS; FEMALE; HUMANS; ISOPROSTANES; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS;

EID: 37749016410     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-007-0610-z     Document Type: Article

References (52)

1. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. The Lancet Neurology 5:228-234
2. Andreasen N, Minthon L, Vanmechelen E (1999) Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 273:5-8
3. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and B-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59:1729-1734
4. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow, et al. (2004) Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9:705-710
5. Herukka SK, Hallikainen M, Soininen H, Pirttila T (2005) CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurol 64:1294-1297
6. Arai H, Ishiguro K, Ohna H, Moriyama M, Itoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Imahori K (2000) CSF phosphorylated tau protein and mild cognitive impairment: A prospective study. Exp Neurol 166:201-203
7. Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann- Kiefer K, McCulloch C, Ptok U, Heun R, Andreasen N, DeBernardis J, Kerkman D, Moeller HJ, Davies P, Hampel H (2002) CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurol 59:627-629
8. Brys M, Mosconi L, De Santi S, Rich KE, de Leon MJ (2006) CSF Biomarkers for Mild Cognitive Impairment. Aging Health 2:111-121
9. Glodzik-Sobanska L, Rusinek H, Mosconi L, Li Y, Zhan J, De Santi S, Convit A, Rich KE, Brys M, de Leon MJ (2005) The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease. Neuroimaging Clinics of North America 15:803-826
10. de Leon MJ, Klunk WE (2006) Biomarkers for the early diagnosis of Alzheimer's disease. The Lancet Neurology 5:198-199
11. Hampel H, Buerger K, Kohnken R, Teipel SJ, Zinkowski R, Moeller HJ, Rapoport SI, Davies P (2001) Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 49:545-546
12. de Leon MJ, Segal CY, Tarshish CY, De Santi S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W, Saint- Louis LA, DeBernardis J, Kerkman D, Qadri F, Gary A, Lesbre P, Wisniewski H, Poirier J, Davies P (2002) Longitudinal CSF tau load increases in mild cognitive impairment. Neurosci Lett 333:183-186
13. Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD (2002) Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med 33:620-626
14. de Leon MJ, De Santi S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, et al. (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27:394-401
15. Quinn JF, Montine KS, Moore M, Morrow JD, Kaye JA, Montine TJ (2004) Suppression of longitudinal increase in CSF F_2-isoprostanes in Alzheimer's disease. J Alz Dis 6:93-97
16. Reisberg B, Ferris SH, de Leon MJ, Crook T (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiat 139:1136-1139
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurol 34:939-944
18. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). Washington, D. C.: American Psychiatric Association
19. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, Fitzgerald GA (2000) Increased 8, 12-iso-iPF2alpha- VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48:809-812
20. Kluger A, Ferris SH, Golomb J, Mittelman, MS, Reisberg B (1999) Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriat Psychiat Neurol 12:168-179
21. De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Boppana M, Tsui WH, Daisley K, Wang GJ, Schlyer D (2001) Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22:529-539
22. Ashburner J, Friston KJ (2000) Voxelbased morphometry - the methods. Neuroimage 11:805-821
23. Good CD, Scahill RI, Fox NC, Ashburner J, Friston KJ, Chan D, Crum WR, Rossor MN, Frackowiak RSJ (2002) Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage 17:29-46
24. Talairach J, Tournoux P (1988) Co-Planar stereotaxic atlas of the human brain. Stuttgart: Thieme
25. Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ (1995) Statistical parametric maps in functional imaging: A general linear approach. Human Brain Mapping 2:189-210
26. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RSJ (2001) A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14:21-36
27. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ (1991) Comparing functional (PET) images: the assessment of significant change. Journal of Cerebral Blood Flow and Metabolism 11:690-699
28. Friston K, Ashburner J, Frith C, Poline J-B, Heather J, Frackowiak R (1995) Spatial registration and normalization of images. Hum Brain Mapp 3:165-189
29. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE (1995) A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of Fluorine-18- FDG PET. The J Nucl Med 36(7):1238-1248
30. Diggle PJ, Heagerty P, Liang K-Y, Zeger SC (2002) Analysis of Longitudinal Data. New York: Oxford University Press
31. Friston KJ, Stephan KE, Lund TE, Morcom A, Kiebel SJ (2004) Mixedeffects and fMRI studies. Neuroimage 24:244-252
32. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow, et al. (1999) Increased CSF F2-isoprostane concentration in probable AD. Neurol 52:562-565
33. Pratico D, Clark CM, Liun F, Lee VY, Trojanowski JQ (2002) Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 59:972-976
34. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58(5):730-735
35. Rusinek H, De Santi S, Frid D, Tsui W, Tarshish C, Convit A, de Leon MJ (2003) Regional brain atrophy rate predicts future cognitive decline: 6- year longitudinal MR imaging study of normal aging. Radiology 229:691-696
36. den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler M (2006) Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiat 63:57-62
37. Morrison JH, Hof PR (1997) Life and death of neurons in the aging brain. Science 278:412-419
38. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EKM, Jones PKP, Ghanbari HA, Wataya AT, Shimohama S, Chiba S, Atwood C, Petersen RBP, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60(8):759-767
39. Pratico D, Uryu K, Leight S, Trojanowski JQ, Lee VMY (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21:4183-4187
40. Matsuoka Y, Picciano M, La Francois J, Duff K (2001) Fibrillar (beta)-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neurosci 104:609-613
41. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttila T, Schapiro M, Rapoport S, Moller HJ, Davies P, Hampel H (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59:1267-1272
42. Buerger K, Zinkowski R, Teipel SJ, Arai H, DeBernardis J, Kerkman D, McCulloch C, Padberg F, Faltraco F, Goernitz A, Tapiola T, Rapoport SI, Pirttila T, Moller HJ, Hampel H (2003) Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiat 160:376-379
43. Buerger K, Otto M, Teipel SJ, Zinkowski R, Blennow K, DeBernardis J, Kerkman D, Schroder J, Schonknecht P, Cepek L (2006) Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging 27:10-15
44. Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, Miura M, Machida N, Lee VM, Trojanowski JQ, Sasaki H (1997) Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 236:262-264
45. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Steinacker P, Ciesielczyk B, Neubert K, Wiltfang J, Kretzschmar HA, Poser S, Otto M (2005) Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J Neural Transm 112:933-948
46. Yao Y, Zhukareva V, Sung S, Clark CM, Rokach J, Lee VMY, Trojanowski JQ, Pratico D (2003) Enhanced brain levels of 8, 12-iso-iPF2-VI differentiate AD from frontotemporal dementia. Neurol 61:475-478
47. Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF (2001) Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med 125:510-512
48. Lin CL, Hsu YT, Lin TK, Morrow JD, Hsu JC, Hsu YH, Hsieh TC, Tsay PK, Yen HC (2006) Increased levels of F2- isoprostanes following aneurysmal subarachnoid hemorrhage in humans. Free Radic Biol Med 40:1466-1473
49. Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23:298-304
50. De Caterina R, Cipollone F, Filardo FP, Zimarino M, Bernini W, Lazzerini G, Bucciarelli T, Falco A, Marchesani P, Muraro R, Mezzetti A, Ciabattoni G (2002) Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 106:2543-2549
51. Pratico D, Lawson JA, Rokach J, Fitzgerald GA (2001) The isoprostanes in biology and medicine. Trends in Endocrinology and Metabolism 12:243-247
52. Ding T, Yao Y, Pratico D (2005) Increase in peripheral oxidative stress during hypercholesterolemia is not reflected in the central nervous system: evidence from two mouse models. Neurochemistry International 46:435-439